NCT05900908 2025-04-10
PATHWAyS
GT Medical Technologies, Inc.
Phase 4 Withdrawn
Clinical Trials
27 trialsNCT05940844 2025-04-09
Study of OB-002 in Patients With Refractory Metastatic Cancer
Orion Biotechnology Polska Sp. z o.o.
Phase 1 Withdrawn
NCT06395090 2025-04-08
MK-9999-01B
Merck Sharp & Dohme LLC
Phase 1/2 Withdrawn
NCT05828303 2025-04-01
A Phase 1 Study to Evaluate the Potential Drug Interactions Between Repotrectinib and Metformin, Digoxin, and Rosuvastatin in Patients With Advanced Solid Tumors
Turning Point Therapeutics, Inc.
Phase 1 Withdrawn
NCT06681870 2025-01-15
A Study of ASP1893 in Adults With Advanced CLDN6-positive Solid Tumors
Astellas Pharma Inc
Phase 1 Withdrawn
NCT06099418 2024-09-20
Efficacy and Safety of VB10.16 Alone or in Combination With Atezolizumab in Patients With Advanced Cervical Cancer.
Nykode Therapeutics ASA
Phase 2 Withdrawn
NCT04294875 2024-03-06
MPT0B64
J Ints Bio
Phase EARLY_PHASE1 Withdrawn
NCT05600582 2023-10-18
A Study of CodaLytic, an Intratumoral Oncolytic Virus, in Patients With Breast Cancer
Codagenix, Inc
Phase 1 Withdrawn
NCT05828277 2023-09-26
A Phase 1 Study to Assess the Effect of Hepatic Impairment on the Pharmacokinetics of Repotrectinib in Advanced Cancer Patients
Turning Point Therapeutics, Inc.
Phase 1 Withdrawn
NCT05561491 2023-06-22
A Study of ONCOS-102 in Combination With Other Novel Immune-therapies in Advanced Treatment-resistant Melanoma Patients
Targovax ASA
Phase 2 Withdrawn
NCT05730673 2023-02-17
Leronlimab in Combination With Regorafenib in Patients With CCR5+, Metastatic Colorectal Cancer
CytoDyn, Inc.
Phase 2 Withdrawn
NCT02201381 2022-07-18
METRICS
Health Clinics Limited
Phase 3 Withdrawn
NCT04465734 2022-05-05
A Clinical Study to Compare the Efficacy and Safety of HLX10 in Combination With HLX04 Versus Sorafenib as the First-line Treatment in Patients With Locally Advanced or Metastatic HCC
Shanghai Henlius Biotech
Phase 3 Withdrawn
NCT04832438 2022-02-22
9-ING-41 Plus Carboplatin in Patients With Advanced, Metastatic Salivary Gland Carcinoma
Actuate Therapeutics Inc.
Phase 2 Withdrawn
NCT04430933 2021-08-18
A Safety and Tolerability Study of NC318 in Combination With Chemotherapy for Subjects With Advanced or Metastatic NSCLC
NextCure, Inc.
Phase 1/2 Withdrawn
NCT01461252 2021-07-16
Safety and Efficacy of Cryoablation Combined With Radiation Therapy for the Palliation of Painful Bone Metastases
Boston Scientific Corporation
Phase 1 Withdrawn
NCT04464967 2021-05-12
Safety and Preliminary Efficacy of SNK01 in Combination With Trastuzumab or Cetuximab in Subjects With Advanced HER2 or EGFR Cancers
NKGen Biotech, Inc.
Phase 1/2 Withdrawn
NCT02831491 2020-06-09
A Study of Ramucirumab (LY3009806) in Combination With Weekly Docetaxel in Participants With Stage IV Non-Small Cell Lung Cancer
Eli Lilly and Company
Phase 2 Withdrawn
NCT03811418 2019-11-26
ATTILA
iOMEDICO AG
Phase 3 Withdrawn
NCT02929576 2018-10-22
ENDEAR
Pfizer
Phase 3 Withdrawn
NCT00615524 2018-01-12
Phase II Study Evaluating Exemestane Alone Or In Combination With Pazopanib In Postmenopausal Women With Hormone Receptor Positive Breast Cancer
GlaxoSmithKline
Phase 2 Withdrawn
NCT02722551 2018-01-09
RELIEF
Edwards Lifesciences
Phase 1/2 Withdrawn
NCT00478270 2017-08-16
A Study of Loading Doses of Intravenous Bondronat (Ibandronate) in Patients With Breast Cancer and Metastatic Bone Disease.
Hoffmann-La Roche
Phase 2 Withdrawn
NCT00386516 2017-08-01
Study to Test the Benefit and Safety of GM-CT-01 in Combination With 5-FU to Treat Bile Duct and Gall Bladder Cancer
Galectin Therapeutics Inc.
Phase 2 Withdrawn
NCT00620607 2015-08-26
huC242-DM4 Treating Patients With Metastatic Gastric or Gastroesophageal Junction Carcinomas
ImmunoGen, Inc.
Phase 2 Withdrawn
NCT00697060 2015-06-24
A Safety and Efficacy Trial of Amplimexon Plus Taxotere in Metastatic Non-Small Cell Lung Cancer
AmpliMed Corporation
Phase 2 Withdrawn
NCT01830322 2013-08-14
Safety and Effectiveness Study of CPI-613 and/or Gemcitabine to Treat Metastatic Pancreatic Cancer
Cornerstone Pharmaceuticals
Phase 2 Withdrawn